NCT00391248

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Ontario Clinical Oncology Group (OCOG) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To improve the clinical outcomes of patients with non-small cell lung cancer treated with radiation therapy.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Erlotinib	150 mg in a single daily dose, starting Day 1 through Day 22

Timeline

• Start date: 2006-11-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2006-10-23
• Last updated: 2013-01-29

Locations

2 sites across 1 country: Canada